Follistatin dosage

Follistatin dosage guidance

AAV1.CMV.FS344 gene transfer uses 3 × 10¹¹ or 6 × 10¹¹ vector genomes/kg per leg, delivered once by intramuscular injections into both quadriceps. These are viral-vector amounts for a gene therapy, not microgram doses of follistatin protein; a standalone protein-vial dose remains unestablished.[1]

Follistatin binds activins and myostatin. Gene-transfer products, full-length proteins and products labeled follistatin-344 differ in exposure and cannot share one dosing regimen.[2][3][4][5]

Follistatin intravenous — nonhuman-primate protein experiment dosage

The published nonhuman-primate IV exposure uses recombinant follistatin at 90 or 180 mcg/kg in a single administration with an activin or GnRH challenge. No corresponding human IV protein amount or repeat-treatment course is established.[7]

Follistatin binds activins and myostatin. Gene-transfer products, full-length proteins and products labeled follistatin-344 differ in exposure and cannot share one dosing regimen.[7][4][5]

Frequency and timing

There is no established meal, exercise or bedtime timing for standalone follistatin protein.[1][5]

Cycle length and breaks

Intramuscular — AAV1-FS344 gene transfer: One administration to both quadriceps. Intravenous — nonhuman-primate protein experiment: Single challenge experiment. A standard break interval between courses is not established.[1][7]

Approval and product quality

Follistatin is not an FDA-approved drug.[10]

Side effects and long-term safety

Reproductive-hormone effects, interactions and long-term safety remain uncertain.[5][8][9]

Route-specific dosing limits

Reduced vision and retinal fluid accumulation were reported in eleven bodybuilders after products labeled follistatin-344. This uncontrolled series cannot establish causation or an adverse-event rate, and product identity is a separate concern.[8][9]